CoChat

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

Open access

The DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.

Abstract

BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).

Verified 2026-10-06 · 3 references not checked yet

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1304839

Cites

31 of 34 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations

40 more claims

Create a free account to see all 57 claims and to verify the 18 references still open.

See all claims — free account
  • It may state two separate claims as one. 6
  • Probably not a substantial claim. 9
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 34 references

Cited by

Metadata

Authors
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
Affiliations
  • Brigham and Women's Hospital (US)
  • UCL Queen Square Institute of Neurology (GB)
  • Sahlgrenska University Hospital (SE)
  • University of Pittsburgh (US)
  • Veterans Health Administration (US)
  • Columbia University (US)
  • University of Rochester Medicine (US)
  • NYU Langone Health (US)
  • Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
  • University of California San Diego (US)
  • Pfizer (United States) (US)
Venue
New England Journal of Medicine
Published
2014-01-23
Volume
370
Issue
4
Pages
322-333
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2063808031
Cited by
1,960
References
35
Citations by year
2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
FWCI
158.46
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • U.S. Department of Veterans Affairs (IK2 BX001820)
  • National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
  • Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
  • National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
  • National Institute of Neurological Disorders and Stroke (R01NS080820)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.